ARNI Stock Overview
A biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Arno Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0003 |
| 52 Week Low | US$0.000058 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -94.12% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ARNI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -1.6% |
| 1Y | n/a | 19.8% | 30.8% |
Return vs Industry: Insufficient data to determine how ARNI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ARNI performed against the US Market.
Price Volatility
| ARNI volatility | |
|---|---|
| ARNI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ARNI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ARNI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | n/a | www.arnothera.com |
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company’s product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets.
Arno Therapeutics, Inc. Fundamentals Summary
| ARNI fundamental statistics | |
|---|---|
| Market cap | US$4.93k |
| Earnings (TTM) | -US$13.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ARNI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARNI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.70m |
| Earnings | -US$13.70m |
Last Reported Earnings
Sep 30, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ARNI perform over the long term?
See historical performance and comparison